Abstract Several sesquiterpenes isolated from a Formosan gorgonian coral Isis hippuris have shown significant cytotoxic activity against various cancer cell lines. In order to search other active components, we have investigated the chemical constituent of I. hippuris from a Green Island specimen. In the cytotoxcity assay, the EtOAc extract showed potent cytotoxic response toward P-388, A549 and HT-29 cancer cell lines. Thus, the investigation on the chemical content of this extract was carried out. This study finally led to the isolation of twelve steroids(1-12). Nine metabolites, hippuristerone G (1)¡Bhippuristerone H (2), hippuristerone I (3)¡Bhippuristerone J (4)¡Bhippuristerol E (5)¡B2a,3a-diacetoxy-24-methyl- 11b,18; 18,20b; 22,25-triepoxy-5a-furostane (7)¡B2a,3a-diacetoxy-11b- hydroxy-24-methyl-22,25-epoxy-5a-furostan-18,20b-lactone (10)¡B3a- acetoxy-11b,18a-dihydroxy-24-methyl-18,20b; 22,25-diepoxy-5a- furostane (11) and 2a,3a-diacetoxy-11b,18a-dihydroxy-24-methyl-18, 20b; 22,25-diepoxy-5a-furostane (12) are new compounds, whereas hippuristerone A (6), 3a-acetoxy-24-methyl-11b,18; 18,20b; 22,25- triepoxy-5a-furostane (7) and 3a-acetoxy-11b-hydroxy-24-methyl-22,25- epoxy-5a-furostan-18,20b-lactone (9) are known compounds. The structures of 1-12 were elucidated by spectroscopic evidences (IR, MS, 1D NMR, 2D NMR) and chemical method. The stereochemistries of compounds 7 and 9 were further confirmed by single-crystal X-ray diffraction analyses. Cytotoxicity test revealed that hippuristerone I (3) exhibited moderate inhibition toward NCI cancer cell line.

Thesis (Ph. D.)--University of Missouri-Columbia, 2000. / Typescript. Vita. Includes bibliographical references. Also available on the Internet.

Thesis (Ph. D.)--University of Missouri-Columbia, 2001. / Typescript. Vita. Includes bibliographical references. Also available on the Internet.

Thesis (Ph. D.)--University of Missouri-Columbia, 2001. / Typescript. Vita. Includes bibliographical references. Also available on the Internet.

Thesis (Ph. D.)--University of Missouri-Columbia, 2000. / Typescript. Vita. Includes bibliographical references. Also available on the Internet.

The production of new drugs as potential pharmaceutical targets is arguably one of the most important avenues of medicine, as existing diseases not only require treatment, but it is also certain that new diseases will appear in the future which will need treatment. Indeed, existing medicines such as antibiotics and immunosuppressants maintain their current activities in their respective realms, yet the molecular and stereochemical complexity of these compounds cause a burden on organic synthetic chemists that may prohibit the high yields required to manufacture a drug. The enzyme systems that naturally manufacture these compounds are incredibly efficient in doing so, and also do not use environmentally harmful solvents, chiral auxiliaries, or metals that are utilized in the current syntheses of these compounds; therefore utilizing these enzymes' machinery for the biocatalysis of new medicinally-relevant compounds, as researchers have in the past, is undeniably a rewarding endeavor. In order to harness these systems' biocatalytic potential, we must understand the processes which they operate. This work focuses on ketoreductase domains, since they are responsible for setting most of the stereocenters found within these complex secondary metabolites. We have supplied a library of substrates to multiple ketoreductases to test their limits of stereospecificity and found that, for the most part, they maintain their natural product stereospecificity seen in nature. We were even able to convert a previously nonstereospecific ketoreductase to a stereospecific catalyst. We have also developed a new technique to follow ketoreductase catalysis in real-time, which can also differentiate between which diastereomeric product is being produced. Finally, we have elucidated the structure of a ketoreductase that reduces non-canonically at the [alpha]- and [beta]- position, and functionally characterized its activities on shortened substrate analogs. With the knowledge gained from this dissertation we hope that the use of ketoreductases as biocatalysts in the biosynthesis of new natural product-based medicines is a much nearer reality than before. / text

Total syntheses of the neuroregenerative natural products vinaxanthone and xanthofulvin have been accomplished. The synthetic routes to both molecules utilize a highly regioselective furan Diels-Alder cycloaddition - aromatization sequence to furnish the catechol fragment present in both natural products. The pentasubstituted catechol was elaborated to a vinylogous amide which was used twice in both syntheses, exploiting the pseudosymmetry found in vinaxanthone and xanthofulvin. This approach enabled the dimerization of 5,6-dehydropolivione forming vinaxanthone, lending significant evidence to a non-enzymatically driven formation of vinaxanthone in Nature. The total synthesis of vinaxanthone was accomplished in nine steps, the shortest synthesis to date, and an additional route was devised to access a set of analogs for biological study. The first total synthesis of xanthofulvin was accomplished in 18 steps and the convergent nature of the synthetic plan allows for analog synthesis. The sets of vinaxanthone and xanthofulvin analogs will be used to examine their inhibition of Semaphorin3A, a protein which inhibits neuronal regeneration, and is the biological target for both molecules.

Chaperone proteins such as heat-shock proteins 70, 90 and 110, glucose-related protein 94 and calreticulin have been reported to be effective anti-tumor vaccines when purified from a tumor source. We have developed a procedure utilizing a free-solution-isoelectric focusing technique to obtain vaccines from tumor or normal tissue sources that are rich in multiple immunogenic chaperone proteins, called Chaperone-Rich Cell Lysate (CRCL). Tumor-associated peptides are presumed to be the currency of T-cell mediated anti-cancer immunity, and tumor-derived chaperone vaccines are believed to be purveyors of such peptides. As a novel anti-cancer strategy, we have examined the extent to which the peptide repertoire of CRCL can be manipulated. Here, we explored the concept of creating a designer CRCL, utilizing the adjuvant properties and the carrying capacity of CRCL to deliver exogenous antigenic peptides for DC-based presentation and ultimately demonstrate the anti-tumor efficacy of the designer vaccine in vivo. Designer CRCL allows for the development of personalized vaccines to those afflicted with cancer expressing known antigens.Growing evidence indicates that the stress response, specifically involving HSPs, has a profound impact on tumor immunogenicity. Enhancement of T-cell-mediated immunogenicity correlates with the expression of inducible heat shock protein 70 (iHSP70), the major heat-inducible member of the HSP70 family. In addition, studies have shown tumor-specific cell surface localization of iHSP70 correlates with an increased sensitivity to lysis mediated by human natural killer (NK) cells. Given these findings, investigating novel and effective means of modulating the heat shock response within tumor cells may bear great therapeutic potential and result in potent anti-tumor immune activity. Withaferin A (WA) is a compound isolated from the plant Withania somnifera that has been shown to induce a robust transcriptional heat shock response. In our studies, we found that WA treatment resulted in increased surface expression of iHSP70 in several tumor types leading to significant immunostimulatory effects. These findings indicated that WA-dependent modulation of the heat shock response may enhance tumor immunogenicity. Given the potent immunomodulatory and anti-tumor effects of WA as well as the adjuvanticity and specificity of peptide-complexed CRCL against tumors, these therapies individually have shown profound anti-cancer activity.

No description available.

Natural compounds have been largely excluded from characterization via high-throughput profiling strategies due to their limited abundance. Herein, I describe the modification of high-throughput yeast chemical genomic (CG) interaction profiling to permit identifying the modes of action of natural compounds. The previous assay proceeded by evaluating the genome-wide yeast deletion collection for drug-hypersensitivity in a volume of 0.7mL. Compound consumption was minimized with the adapted approach by reducing the assay volume 70% through simplifying the complexity of the yeast deletion pool screened. By recreating each yeast mutant in a drug-hypersensitive background, I created a novel resource that increases compound efficiency and further diminishes compound use. Evaluating a series of characterized compounds analyzed previously by the traditional CG approach validated the adaptations incorporated did not negatively affect the quality of data yielded. Ultimately, this modified strategy will be used to screen thousands of natural compounds contained within the RIKEN NPDepo library.